Search Results - "SNYDER, MARGO"

A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer by Aggarwal, Rahul R, Schweizer, Michael T, Nanus, David M, Pantuck, Allan J, Heath, Elisabeth I, Campeau, Eric, Attwell, Sarah, Norek, Karen, Snyder, Margo, Bauman, Lisa, Lakhotia, Sanjay, Feng, Felix Y, Small, Eric J, Abida, Wassim, Alumkal, Joshi J

“…ZEN-3694 is a bromodomain extraterminal inhibitor (BETi) with activity in androgen-signaling inhibitor (ASI)-resistant models. The safety and efficacy of…”
Get full text

754-P: A First-in-Human Single Ascending Dose Study of GSBR-1290, a Novel Small Molecule GLP-1 Receptor Agonist, in Healthy Volunteers by COLL, BLAI, ZHANG, JINQIANG J., JACOBER, SCOTT J., ARGENT, CHRISTOPHER, IBARRA, LANI, SNYDER, MARGO, BACH, MARK A.

“…Introduction: Type 2 Diabetes Mellitus (T2DM) and obesity incidences are rising globally. The risk:benefit ratio of peptide GLP-1 receptor agonists (RAs) has…”
Get full text

A randomized mCRPC phase 2b study of the BET bromodomain inhibitor (BETi) zen-3694 and enzalutamide vesus enzalutamide by Aggarwal, Rahul Raj, Schweizer, Michael Thomas, Nanus, David M., Attwell, Sarah, Campeau, Eric, Johnson, Emily, Wegge, Philip, Bauman, Lisa, Silverman, Michael H., Xu, Vandy, Zhu, Helena, Snyder, Margo, Lakhotia, Sanjay, Alumkal, Joshi J.

“…Abstract only TPS201 Background: Androgen receptor signaling inhibitors (ARSI), such as enzalutamide (Enza), and abiraterone (Abi), are standard therapies for…”
Get full text

A phase 1b/2 study of the BET inhibitor ZEN-3694 in combination with talazoparib for treatment of patients with TNBC without gBRCA1/2 mutations by Aftimos, Philippe Georges, Oliveira, Mafalda, Punie, Kevin, Boni, Valentina, Hamilton, Erika P., Gucalp, Ayca, Shah, Payal D, de Miguel, Maria J., Sharma, Priyanka, Bauman, Lisa, Campeau, Eric, Attwell, Sarah, Snyder, Margo, Norek, Karen, Johnson, Emily, Silverman, Michael H., Lakhotia, Sanjay, Domchek, Susan M., Litton, Jennifer Keating, Robson, Mark E.

“…1023 Background: Metastatic triple negative breast cancer (mTNBC) is an aggressive and heterogeneous cancer with limited therapeutic options. PARP inhibitors…”
Get full text

A Phase 1b/2a Study of the Pan-BET Bromodomain Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer by Aggarwal, Rahul, Schweizer, Michael T., Nanus, David M., Pantuck, Allan, Heath, Elisabeth, Campeau, Eric, Attwell, Sarah, Norek, Karen, Snyder, Margo, Bauman, Lisa, Lakhotia, Sanjay, Feng, Felix Y., Small, Eric J., Abida, Wassim, Alumkal, Joshi

Get full text

Abstract PS11-10: A Phase 1b/2 Study of the BET inhibitor ZEN003694 in combination with talazoparib for treatment of patients with TNBC without gBRCA1/2 mutations by Aftimos, Philippe, Oliveira, Mafalda, Punie, Kevin, Boni, Valentina, Hamilton, Erika, Gucalp, Ayca, Shah, Payal, Mina, Lida, Sharma, Priyanka, Bauman, Lisa, Campeau, Eric, Attwell, Sarah, Snyder, Margo, Norek, Karen, Czibere, Akos, Yu, Yanke, Silverman, Michael H, Lakhotia, Sanjay, Domchek, Susan, Litton, Jennifer, Robson, Mark

“…Background: Metastatic triple-negative breast cancer (TNBC) is an aggressive and heterogeneous cancer with limited therapeutic options. PARP inhibitors (PARPi)…”
Get full text

Abstract CT095: A Phase Ib/IIa study of the BET bromodomain inhibitor ZEN-3694 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) by Aggarwal, Rahul, Abida, Wassim, Schweizer, Michael, Pantuck, Allan, Nanus, David, Heath, Elisabeth, Lakhotia, Sanjay, Hansen, Henrik, Silverman, Michael, Bauman, Lisa, Snyder, Margo, Campeau, Eric, Norek, Karen, Attwell, Sarah, O'Farrell, Marie, Smith, Steve, Wegge, Philip, Jahagirdar, Ravi, Alumkal, Joshi

“…Background: Abiraterone (ABI) and enzalutamide (ENZ) have significant activity in mCRPC yet demonstrate frequent cross-resistance limiting efficacy of…”
Get full text

Managed care programs: an employer perspective by Carroll, M S

“…Throughout the 1980s, employers made many health care benefit plan modifications that were directed toward containing costs. This chapter discusses potential…”
Get more information